U-Protein Express BV is a dedicated CRO that has many years experience in recombinant protein production. At U-Protein Express BV fully post-translational modified mammalian recombinant proteins or recombinant antibodies are produced via its r-PEx transient protein production platform. The r-PEx expression platform is based on HEK293 and CHO cell lines and yields 1 mg to 1 gram amount of recombinant protein in 4-6 weeks. In addition, custom monoclonal antibodies can be produced via classical hybridoma technology.

If you need more information please send us an email and we will contact you as soon as possible.

May 30th, 2018:

ImmunoPrecise increases private placement financing. The financing will be used to expand operations and sales in the United States, Canada and Europe.

May 29th, 2018:

ImmunoPrecise announces private placement financing. The financing will be used to expand operations and sales in the United States, Canada and Europe.

May 24th, 2018:

ImmunoPrecise appoints Jennifer Bath to Board of Directors and expands senior leadership to further global growth.

May 18th, 2018:

ImmunoPrecise opens new US Headquarters in Fargo, North Dakota.

April 27th, 2018:

ImmunoPrecise Opens New Full Service B-Cell Facility.

April 6th, 2018:

ImmunoPrecise Antibodies Ltd. closes acquisition ModiQuest BV.

April 6th, 2018:

ImmunoPrecise Antibodies Ltd. announces oversubscription to debenture financing.

March 29th, 2018:

ImmunoPrecise Antibodies Ltd. reports third quarter 2018 financial results.

March 16th, 2018:

ImmunoPrecise enters into definitive agreement to acquire Modiquest Research BV.

February 09th, 2018:

U-Protein Express has a job position available for a talented protein chemist. The job description can be found here (Dutch).

February 08th, 2018:

ImmunoPrecise appoints new President and CEO.

January 22nd, 2018:

ImmunoPrecise to strategically invest in foundational Next Generation Antibody Discovery technology.

January 18th, 2018:

ImmunoPrecise Engages San Francisco Based LightPath Capital as a Key Partner in its Financing Strategy.

January 2nd, 2018:

ImmunoPrecise Antibodies Ltd. and U-Protein Express BV announce that ImmunoPrecise will attend the J.P. Morgan 36th Annual Healthcare Conference running from January 8-11, 2018 in San Francisco, California.

December 29th, 2017:

ImmunoPrecise Antibodies to invest in SERPINx BV.

December 28th, 2017:

ImmunoPrecise Antibodies to acquire Preclinics GmbH.

December 22nd, 2017:

ImmunoPrecise Antibodies to acquire Crossbeta Biosciences BV.

December 7th, 2017:

ImmunoPrecise Antibodies to acquire ModiQuest Research BV.

October 25th, 2017:

Meet U-Protein Express BV at the 2017 PEGS summit in Lisbon.

October 2nd, 2017:

U-Protein Express BV and ImmunoPrecise Antibodies announce acquisition of QVQ Holding BV.

September 18th, 2017:

ImmunoPrecise Antibodies starts first humanized antibodies projects.

September 12th, 2017:

U-Protein Express and ImmunoPrecise Antibodies merge.

June 8th, 2017:

Meet U-Protein Express BV at the 2017 BIO international convention in San Diego.

April 3rd, 2017:

U-Protein Express BV has moved to a new location (Dutch).

March 17th, 2017:

U-Protein Express BV acquires a major stake in QVQ BV, a company specialized in the generation of VHH molecules.

January 12st, 2017:

U-Protein Express BV receives MIT R&D collaborative project subsidy from the Economic Board Utrecht.

April 24st, 2016:

U-Protein Express acquires patent rights on mutated human surfactant protein D as broad anti-influenza therapeutic from the Utrecht University.

October 29st, 2015:

U-Protein Express joins European Commission’s Marie Curie Innovative Training Network Programme PolarNet.

March 31st, 2015:

U-Protein Express, Utrecht University and GenMab receive a NWO grant for the production of tumor markers and novel antibodies (Dutch).

June 23rd, 2014:

U-Protein Express starts collaboration with Utrecht University on the generation of nanobodies. These nanobodies or Llama VHH domains are generated against human receptors.

December 25th, 2012:

U-Protein Express receives US patent covering a method on protein sequencing using Lys-N. The press release can be found here.

November 1st, 2012:

Job position available at U-Protein Express BV for a laboratory scientist with experience in molecular biology, cell culture and protein purification. A detailed description can be found here (Dutch).

September 17th, 2012:

U-Protein Express BV announces that it has closed a non-exclusive license agreement with ImmunoPrecise Antibodies Ltd. for their proprietary r-PEx transient HEK293-based expression platform for the production of recombinant antibodies.


January 27th, 2012:

U-Protein Express BV, Crossbeta Biosciences and Good Biomarker Sciences join forces to develop Alzheimer’s disease biomarker with a grant from IPC-BioFarmind.

December 1st, 2011:

U-Protein Express BV acquires patent rights for protein sequencing by mass spectroscopy from the Utrecht University, The Netherlands. Download the press release.

May 24-26 2011:

Visit us at the Recombinant Antibodies Conference 2011 in Barcelona.

April 3-7 2011:

Read our advertisement for Lys-N at the Proteomic Forum, Berlin, page 34.

October 5-7 2010:

Visit us at Biotechnica, Hannover.

August 2010:

First publication for the use of recombinant Lys-N in Biochemistry.

June 7th, 2010:

Prof. Dr. Piet Gros receives  Spinoza Prize.

May 29th, 2010:

ArGEN-X licenses r-PEx technology. Press release May 2010.

October 20th, 2009:

Visit us at Life Sciences Momentum 2009.

September 2009:

Launch of recombinant Lys-N for protein sequencing by Mass Spectroscopy. Download the flyer here.

January 2009:

U-Protein Express BV joins CTMM-predicct.

December 2008:

FND-Innovation project approved.

April 2008:

U-Protein Express BV sponsors Bijvoet 20th annual symposium.

November 2007:

FND-Feasibility approved.

November 2007:

Transition of ABC expertise center "Expression Center" to U-Protein Express BV (publication in Dutch).